|
Olympus Corporation (7733.T) Évaluation DCF
JP | Healthcare | Medical - Instruments & Supplies | JPX
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Olympus Corporation (7733.T) Bundle
Simplifier l'Olympus Corporation (7733T) Évaluation avec cette calculatrice DCF personnalisable! Doté de la véritable valeur des finances de la Real Olympus Corporation (7733T), vous pouvez tester les scénarios et découvrir la juste valeur d'Olympus Corporation (7733T) en minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 797,411.0 | 730,544.0 | 868,867.0 | 881,923.0 | 936,210.0 | 978,823.7 | 1,023,377.1 | 1,069,958.4 | 1,118,660.0 | 1,169,578.4 |
| Revenue Growth, % | 0 | -8.39 | 18.93 | 1.5 | 6.16 | 4.55 | 4.55 | 4.55 | 4.55 | 4.55 |
| EBITDA | 158,287.0 | 160,805.0 | 233,165.0 | 238,825.0 | 107,971.0 | 210,075.4 | 219,637.4 | 229,634.7 | 240,087.1 | 251,015.2 |
| EBITDA, % | 19.85 | 22.01 | 26.84 | 27.08 | 11.53 | 21.46 | 21.46 | 21.46 | 21.46 | 21.46 |
| Depreciation | 68,309.0 | 59,937.0 | 64,615.0 | 66,741.0 | 65,940.0 | 75,992.8 | 79,451.8 | 83,068.2 | 86,849.3 | 90,802.4 |
| Depreciation, % | 8.57 | 8.2 | 7.44 | 7.57 | 7.04 | 7.76 | 7.76 | 7.76 | 7.76 | 7.76 |
| EBIT | 89,978.0 | 100,868.0 | 168,550.0 | 172,084.0 | 42,031.0 | 134,082.6 | 140,185.6 | 146,566.5 | 153,237.8 | 160,212.8 |
| EBIT, % | 11.28 | 13.81 | 19.4 | 19.51 | 4.49 | 13.7 | 13.7 | 13.7 | 13.7 | 13.7 |
| Total Cash | 165,918.0 | 227,746.0 | 312,841.0 | 180,689.0 | 340,933.0 | 283,647.3 | 296,558.2 | 310,056.7 | 324,169.6 | 338,924.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 143,062.0 | 157,920.0 | 178,428.0 | 174,672.0 | 197,599.0 | 197,732.9 | 206,733.2 | 216,143.1 | 225,981.3 | 236,267.4 |
| Account Receivables, % | 17.94 | 21.62 | 20.54 | 19.81 | 21.11 | 20.2 | 20.2 | 20.2 | 20.2 | 20.2 |
| Inventories | 167,596.0 | 158,984.0 | 167,368.0 | 162,994.0 | 190,030.0 | 197,374.3 | 206,358.2 | 215,751.1 | 225,571.5 | 235,838.9 |
| Inventories, % | 21.02 | 21.76 | 19.26 | 18.48 | 20.3 | 20.16 | 20.16 | 20.16 | 20.16 | 20.16 |
| Accounts Payable | 59,557.0 | 69,870.0 | 60,547.0 | 62,919.0 | 61,855.0 | 73,886.8 | 77,249.9 | 80,766.1 | 84,442.4 | 88,286.0 |
| Accounts Payable, % | 7.47 | 9.56 | 6.97 | 7.13 | 6.61 | 7.55 | 7.55 | 7.55 | 7.55 | 7.55 |
| Capital Expenditure | -65,929.0 | -59,227.0 | -61,771.0 | -70,623.0 | -64,624.0 | -75,164.0 | -78,585.3 | -82,162.3 | -85,902.1 | -89,812.1 |
| Capital Expenditure, % | -8.27 | -8.11 | -7.11 | -8.01 | -6.9 | -7.68 | -7.68 | -7.68 | -7.68 | -7.68 |
| Tax Rate, % | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 | -576.54 |
| EBITAT | 59,759.4 | 16,964.1 | 130,165.6 | 135,398.6 | 284,355.8 | 90,946.1 | 95,085.7 | 99,413.8 | 103,938.8 | 108,669.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -188,961.6 | 21,741.1 | 94,794.6 | 142,018.6 | 234,644.8 | 96,328.5 | 81,331.2 | 85,033.1 | 88,903.6 | 92,950.3 |
| WACC, % | 6.48 | 6.27 | 6.53 | 6.53 | 6.63 | 6.49 | 6.49 | 6.49 | 6.49 | 6.49 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 369,636.0 | |||||||||
| Long Term Growth Rate, % | 3.00 | |||||||||
| Free cash flow (T + 1) | 95,739 | |||||||||
| Terminal Value | 2,746,122 | |||||||||
| Present Terminal Value | 2,005,629 | |||||||||
| Enterprise Value | 2,375,265 | |||||||||
| Net Debt | -41,317 | |||||||||
| Equity Value | 2,416,582 | |||||||||
| Diluted Shares Outstanding, MM | 1,216 | |||||||||
| Equity Value Per Share | 1,986.93 |
What You Will Receive
- Authentic OLYMPUS Financial Data: Equipped with Olympus Corporation’s historical and forecasted data for accurate analysis.
- Completely Customizable Template: Easily adjust key inputs such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch as Olympus’s intrinsic value changes in real-time with your adjustments.
- Expert Valuation Tool: Created for investors, analysts, and consultants aiming for precise DCF outcomes.
- Intuitive Layout: User-friendly structure with straightforward instructions suitable for all skill levels.
Core Features
- Customizable Forecast Inputs: Adjust vital metrics such as revenue growth, EBITDA %, and capital spending.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and additional financial metrics.
- High-Precision Accuracy: Leverages Olympus Corporation's (7733T) actual financial data for realistic valuation results.
- Effortless Scenario Analysis: Easily experiment with various assumptions and evaluate different outcomes.
- Efficiency Booster: Remove the necessity of constructing intricate valuation models from the ground up.
How It Operates
- Download the Template: Gain immediate access to the Excel-based Olympus Corporation (7733T) DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells to set your growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically recalibrates Olympus Corporation’s intrinsic value.
- Test Scenarios: Experiment with different assumptions to assess how valuations may shift.
- Analyze and Decide: Leverage the outputs to inform your investment strategy or financial analysis.
Why Opt for This Olympus Calculator?
- Precision: Utilizing actual Olympus financial data guarantees reliable insights.
- Versatility: Built for users to effortlessly experiment with and adjust inputs.
- Efficiency: Eliminate the complexity of creating a DCF model from the ground up.
- Professional-Quality: Crafted with the expertise and usability expected at the CFO level.
- Accessible: Simple to navigate, even for those lacking extensive financial modeling knowledge.
Who Should Use Olympus Corporation's (7733T) Products?
- Professional Investors: Develop comprehensive and accurate valuation models for portfolio assessment related to Olympus Corporation (7733T).
- Corporate Finance Teams: Evaluate valuation scenarios to inform internal strategies for Olympus Corporation (7733T).
- Consultants and Advisors: Offer clients precise valuation insights pertaining to Olympus Corporation (7733T).
- Students and Educators: Utilize real-world data for practice and instruction in financial modeling, focusing on Olympus Corporation (7733T).
- Tech Enthusiasts: Gain insights into the market valuation of technology companies like Olympus Corporation (7733T).
Contents of the Template
- Historical Data: Provides an overview of Olympus Corporation’s past financial performance and baseline forecasts.
- DCF and Levered DCF Models: Comprehensive templates designed to assess the intrinsic value of Olympus Corporation (7733T).
- WACC Sheet: Preconfigured calculations for the Weighted Average Cost of Capital.
- Editable Inputs: Customize essential drivers such as growth rates, EBITDA percentages, and CAPEX assumptions.
- Quarterly and Annual Statements: Detailed breakdown of Olympus Corporation's financial statements.
- Interactive Dashboard: Dynamically visualize valuation outcomes and projections.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.